Hugh Taylor
Yale University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Hugh Taylor as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:39 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT06375811 · Pre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_tempYale University · active not recruiting · Infertility, Endometriosis · principal investigator
- Early Ph1NCT05343572 · Bone Marrow Derived Stem Cells Mobilization for Treatment of Abnormal EndometriumHugh Taylor · recruiting · Asherman Syndrome, Atrophic Endometrium, Recurrent Implantation Failure · principal investigator
- Ph1NCT04177693 · Pharmacokinetics and Hepatic Safety of EGCGYale University · completed · Uterine Fibroids · study director
- Ph3NCT04173169 · Pre-IVF Treatment With a GnRH Antagonist in Women With EndometriosisYale University · completed · Infertility, Endometriosis · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:39 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 3 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Large scale genome sequencing and integrative analyses to define genomic predictors of recurrent pregnancy lossR01HD105267 · NICHD · YALE UNIVERSITY · fiscal years 2021 to 2026 · $1,463,819 awarded in 2026Same name and institution; not confirmed by an ID
- The Yale WRHR Career Development CenterK12HD047018 · NICHD · YALE UNIVERSITY · fiscal years 2012 to 2026 · $340,199 awarded in 2026Same name and institution; not confirmed by an ID
- Pre-IVF treatment with a GnRH antagonist in women with endometriosis - A prospective double blind placebo controlled trial (Pregnant) - Application 1/4R01HD100336 · NICHD · YALE UNIVERSITY · fiscal years 2019 to 2023 · $1,007,337 awarded in 2023Grant number is on one of their registry trials
- Reproductive Medicine Collaborative Consortium: a randomized placebo-controlled trial of EGCG to improve fertility in women with uterine fibroids- Application 4/4R01HD100369 · NICHD · YALE UNIVERSITY · fiscal years 2019 to 2023 · $342,628 awarded in 2023Grant number is on one of their registry trials
- Environmental Estrogen Induced Epigenetic Alteration of Uterine Stem CellsR01HD076422 · NICHD · YALE UNIVERSITY · fiscal years 2012 to 2016 · $412,087 awarded in 2016Same name and institution; not confirmed by an ID
- Alteration of HOX Gene Expression by Endocrine Disrupting ChemicalsR01ES010610 · NIEHS · YALE UNIVERSITY · fiscal years 2001 to 2011 · $337,795 awarded in 2011Same name and institution; not confirmed by an ID
- Center for Endometrial Biology and EndometriosisU54HD052668 · NICHD · YALE UNIVERSITY · fiscal years 2007 to 2011 · $1,280,732 awarded in 2011Same name and institution; not confirmed by an ID
- Hox Gene Expression in Human EndometriumR01HD036887 · NICHD · YALE UNIVERSITY · fiscal years 2003 to 2007 · $279,050 awarded in 2007Same name and institution; not confirmed by an ID
- HOX GENE EXPRESSION IN HUMAN ENDOMETRIUMR29HD036887 · NICHD · YALE UNIVERSITY · fiscal years 1998 to 2002 · $120,411 awarded in 2002Same name and institution; not confirmed by an ID
- DETERMINATION OF HOMEOBOX GENE SPECIFICITYK11HD001003 · NICHD · YALE UNIVERSITY · fiscal years 1993 to 1997 · $96,394 awarded in 1997Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 09:39 UTC. The ranking covers the 200 most relevant of 260 PubMed records, and a shared surname and initials can bring in a namesake. All 260 on PubMed
- A randomized trial of adenotonsillectomy for childhood sleep apnea.N Engl J Med · 20131,073 citationsRCR 50.3
- Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist.N Engl J Med · 2017375 citationsRCR 19.9
- 343 citationsRCR 14.2
- Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial.Ann Intern Med · 2014273 citationsRCR 10.0
- Comparison of ivermectin and diethylcarbamazine in the treatment of onchocerciasis.N Engl J Med · 1985250 citationsRCR 11.6
- A randomized placebo-controlled trial of methotrexate in psoriatic arthritis.Rheumatology (Oxford) · 2012245 citationsRCR 9.0
- Comparison of surgical and medical group survival in patients with left main coronary artery disease. Long-term CASS experience.Circulation · 1995239 citationsRCR 6.6
- 187 citationsRCR 7.7
- Prevalence and predictors of open-angle glaucoma: results from the visual impairment project.Ophthalmology · 2001184 citationsRCR 6.6
- Comparison of surgical and medical group survival in patients with left main equivalent coronary artery disease. Long-term CASS experience.Circulation · 1995179 citationsRCR 4.7